Eli Lilly’s bamlanivimab was the first antibody drug the FDA authorized to treat COVID-19. Now, the Indianapolis pharma has data showing the therapy prevents symptomatic infections.
The catch? The data are limited to long-term care facilities, where vaccination is now underway—and despite their utility, antibody thereapies are having a tough time catching on.
Bamlanivimab cut the risk of developing symptomatic COVID-19 by 57% among residents and staffers of long-term care facilities in a phase 3 trial conducted by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), Lilly said Thursday. The risk reduction was higher at 80% among the subgroup of nursing home residents.